AVTR vs. ZTS: Avantor vs. Zoetis Stock Comparison

November 11, 2026

How do Avantor (AVTR) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Avantor (AVTR) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while ZTS is classified in Pharmaceuticals.

Company profile comparison for Avantor (AVTR) and Zoetis (ZTS)
Profile Item	AVTR	ZTS
Name	Avantor, Inc.	Zoetis Inc. Class A Common Stock
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Pharmaceuticals
GICS Sub-Industry	Life Sciences Tools & Services	Pharmaceuticals
Market Capitalization	10.48 billion USD	32.26 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	May 17, 2019	February 1, 2013
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AVTR

ZTS

GSPC

Avantor (AVTR) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Avantor (AVTR) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Avantor (AVTR) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Avantor (AVTR) and Zoetis (ZTS)
Metric	AVTR	ZTS
Total Return (1Y)	36.41%	-30.10%
Total Return (3Y, Annualized)	-5.02%	-20.42%
Total Return (5Y, Annualized)	-16.62%	-16.87%

Risk Profile

Drawdown History

AVTR

ZTS

GSPC

Avantor (AVTR) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Avantor (AVTR) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Avantor (AVTR) and Zoetis (ZTS)
Metric	AVTR	ZTS
Volatility (1Y, Annualized)	43.39%	38.23%
Beta (5Y)	0.94	0.66
Max Drawdown (5Y)	-82.42%	-70.45%
Avg. Volume (3M)	8.56M	4.65M

Risk-Adjusted Performance

Risk-Return Positioning

AVTR and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Avantor (AVTR) and Zoetis (ZTS)
Metric	AVTR	ZTS
Sharpe Ratio (1Y)	0.74	-0.90
Sortino Ratio (1Y)	1.17	-1.10

Profitability

ROE (TTM)

Zoetis (ZTS) at 57.63% sits in the top ROE quartile, while Avantor (AVTR) at 5.91% is closer to the peer norm — stronger capital efficiency for ZTS.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.91%

Max: 109.18%
Q3: 6.23%
AVTR: 5.91%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max: 109.18%
ZTS: 57.63%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Avantor (AVTR) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Zoetis (ZTS) at 26.41% keeps the most of each sales dollar — above its industry’s net margin range — and Avantor (AVTR) at 5.08% also retains a top-quartile share.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.08%

Max: 18.05%
AVTR: 5.08%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS: 26.41%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Avantor (AVTR) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Zoetis (ZTS) at 38.19% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 83.12%
Q3: 14.77%
AVTR: 8.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max: 83.12%
ZTS: 38.19%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Avantor (AVTR) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Avantor (AVTR) and Zoetis (ZTS)
Metric	AVTR	ZTS
ROE (TTM)	5.91%	57.63%
ROA (TTM)	2.83%	14.87%
Net Margin (TTM)	5.08%	26.41%
Operating Margin (TTM)	8.19%	38.19%
Gross Margin (TTM)	31.59%	71.65%

Growth

Revenue Growth

Zoetis (ZTS) at 2.28% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Avantor (AVTR) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Zoetis (ZTS) at 10.05% is around its peer norm for EPS growth, while Avantor (AVTR) at -175.00% drops into the bottom quartile, signaling weaker earnings momentum.

Avantor (AVTR) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Avantor (AVTR) and Zoetis (ZTS)
Metric	AVTR	ZTS
Revenue Growth (YoY)	-3.41%	2.28%
Revenue Growth (3Y CAGR)	-4.46%	5.42%
EPS Growth (YoY)	-175.00%	10.05%
EPS Growth (3Y CAGR)	--	10.27%

Financial Strength

Current Ratio (MRQ)

Both Avantor (AVTR) at 1.89 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.89

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AVTR: 1.89
Min: 0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ZTS: 2.35
Min: 0.10

Avantor (AVTR) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Avantor (AVTR) at 0.63 is near its industry mid-range for debt-to-equity ratio, while Zoetis (ZTS) at 2.80 sits above its benchmark range, pointing to a heavier debt load relative to equity.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.63

Max: 1.42
Q3: 0.65
AVTR: 0.63
Median: 0.15
Q1: 0.02
Min: 0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS: 2.80
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Avantor (AVTR) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Avantor (AVTR) and Zoetis (ZTS)
Metric	AVTR	ZTS
Current Ratio (MRQ)	1.89	2.35
Debt / Equity (MRQ)	0.63	2.80
Net Debt / EBITDA	3.40	1.92

Dividends

Dividend Yield (TTM)

Avantor (AVTR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS: 2.55%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Avantor (AVTR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS: 35.24%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Avantor (AVTR) and Zoetis (ZTS)
Metric	AVTR	ZTS
Dividend Yield (TTM)	0.00%	2.55%
Dividend Payout Ratio (TTM)	0.00%	35.24%

Valuation

P/E Ratio (TTM)

Both Avantor (AVTR) at 30.94 and Zoetis (ZTS) at 13.50 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.94

Max: 85.34
Q3: 43.46
AVTR: 30.94
Median: 26.69
Q1: 13.30
Min: 0.07

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max: 85.34
Q3: 43.46
Median: 26.69
ZTS: 13.50
Q1: 13.30
Min: 0.07

Avantor (AVTR) vs. Zoetis (ZTS): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Zoetis (ZTS) at 3.40 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.58

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
AVTR: 1.58
Min: 0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max: 58.18
Q3: 25.77
Median: 7.30
ZTS: 3.40
Q1: 3.01
Min: 0.01

Avantor (AVTR) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Avantor (AVTR) at 1.80 is valued about in line with its industry on P/B ratio, while Zoetis (ZTS) at 9.80 carries an above-peer premium to book — ZTS is pricier on assets.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.80

Max: 13.53
Q3: 6.54
Median: 3.25
AVTR: 1.80
Q1: 1.69
Min: -5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max: 13.53
ZTS: 9.80
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Avantor (AVTR) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Avantor (AVTR) and Zoetis (ZTS)
Metric	AVTR	ZTS
P/E Ratio (TTM)	30.94	13.50
P/S Ratio (TTM)	1.58	3.40
P/B Ratio (MRQ)	1.80	9.80
Free Cash Flow Yield (TTM)	4.21%	6.36%